7th Supply Chain and Logistics for Cell and Gene Therapies Summit

In 2025, cell and gene therapy reached a pivotal moment. Amid rising tariffs, shifting regulations, and capacity constraints, the industry gained clarity on what it takes to scale successfully. As a result, the focus on scaling novel therapies safely and efficiently has never been stronger, introducing a new era of operational excellence and expanded patient access.
 
As we enter 2026, AI, digitalization, and IoT are transforming how cell and gene therapies are planned, tracked, and delivered end-to-end. With smarter, data-driven decision-making, supply chain teams can better navigate tariff fluctuations, manufacturing variability, and regulatory complexity.
 
Designed by and for supply chain leaders across biopharma, including Roche, Bristol Myers Squibb, Johnson and Johnson, Genentech, ProKidney, and Vyriad the 7th Supply Chain and Logistics for Cell and Gene Therapy Summit delivers best-in-class perspectives on global patient supply, cost of goods optimization, and accelerating clinical and commercial programs through digital innovation. With strong end-to-end focus, the agenda reflects the real challenges facing advanced therapy supply chains today.
 
If you are a supply chain leader in cell and gene therapy, this is your must-attend opportunity to connect with peers, benchmark best practices, and gain actionable insights to build a resilient, future-ready supply chain that delivers therapies to patients, reliably and at scale.